# Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors

Source: https://onco.cc/trials/nct07280832/  
OnCo record `nct07280832` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of JMT108 in melanoma, run by Shanghai JMT-Bio Inc., now recruiting.

## Summary

Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors is a phase 1/2 interventional study registered as NCT07280832 by Shanghai JMT-Bio Inc., with 500 participants planned, started 2025-12-17 and due to reach its primary completion in 2026-11-30. Interventions recorded: JMT108.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07280832
- Phase: 1/2
- Setting: Open-Label, Multicenter Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of JMT108 Injection in Participants With Unresectable or Metastatic Melanoma and Urinary Tract Tumors
- Sponsor: Shanghai JMT-Bio Inc.
- Enrolled: 500

## Sources

- ClinicalTrials.gov NCT07280832: https://clinicaltrials.gov/study/NCT07280832

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)

---
JSON: https://onco.cc/api/v1/entities/nct07280832.json